The digital biomarkers market is growing on the basis of an exorbitant increase in incidence of chronic diseases. Digital biomarkers proffer noteworthy interpretations of digital measurements of a patient along with correlated medical conditions. They capture and analyze array of environmental, behavioral, and physiological data through wearables, sensors, and digital platforms.
The key players in digital biomarkers market are working toward increasing psychophamacology clinical trial success rates with biomarkers and digital measures. They are also exploring the probability of using digital biomarkers for Parkinson’s disease. Application of AI to digital biomarkers in order to improve diagnosis and reduce readmissions is on the anvil.
Digital biomarkers are referred to as objective and quantifiable behavioral and physiological data collected and measured using digital devices such as wearables, portables, ingestibles, or implantables.
In other words, digital biomarkers are the indices that objectively visualize onslaught of a disease and changes caused due to treatment using the data obtained from smartphones and digital devices.
Digital biomarkers are used for personalizing preventive care, evaluating risks, and managing mental health conditions and diseases. Smartphones are the major promoters of adoption of digital biomarkers industry in healthcare.
Smartwatches, smartphones, and medical bracelets are driving the demand for usage of digital biomarkers. Heart rate monitoring and oxygen saturation are the common features of consumer wearables.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
Digital biomarkers are slated to transform the level of medical care for various chronic conditions that are difficult to gauge otherwise. As per the WHO, noncommunicable diseases (NCDs) claim the lives of nearly 41 million individuals every year.
It further states that cardiovascular diseases account for 17.9 million deaths worldwide. Cancers come in second with 9.3 million, chronic respiratory diseases with 4.1 million, and diabetes with 2 million.
Digital biomarkers help healthcare providers to resort to cost-effective targeted preventive/curative measures, i.e. early detection of diseases, and introduction of personalized interventions. These measures, in turn, help in improving the quality of life of the patients.
Need for timely diagnosis of chronic ailments through digital biomarkers is thus accelerating the global digital biomarkers market.
Digital healthcare is being rapidly adopted, which is expediting the process of synthesis of digital biomarkers market. For instance, in February 2023, Koneksa raised US$ 45 Mn in Series C funding.
It was led by Ayur Maya along with participation from Takeda Ventures, Velosity Capital, and existing investors such as McKesson Ventures, Merck Global Health Innovation Fund, Novartis AG, and others.
In March 2022, Mitsubishi Tanabe Pharma America (MTHA) and Everything ALS collaborated with the objective of bridging gap between patients, research, and technology through development of digital biomarkers for amyotrophic lateral sclerosis (ALS).
In October 2022, Spren raised over US$ 1 Mn in seed capital for launching camera-enabled biomarker platform. Around the same time, Koneksa announced launching its clinical pipeline including the biomarkers in respiratory, oncology, neuroscience, and various other therapeutic areas.
Continual adoption of digital healthcare is thus driving the digital biomarkers market growth.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
As per the latest digital biomarkers market insights, North America dominated the digital health analytics industry in 2023 and the scenario is expected to persist during the forecast period. This is attributed to increase in the number of patients suffering from coronary artery disease.
As per the report published by the Centers for Disease Control and Prevention, close to 20.1 million adults in the U.S. live with coronary artery disease, and 805,000 Americans suffer from heart attack every year.
Additionally, as per data published by International Clinical Trials Registry Platform (ICTRP), over 11,000 clinical trials are in the active state in the U.S.
Europe’s significant digital biomarkers market share is ascribed to increase in the number of chronic patients who need real-time diagnostics and monitoring on continuous basis. Moreover, the governments are encouraging excessive R&D activities in this regard.
The companies in digital biomarkers are engaging in new product launch to sustain themselves in the connected health indicators landscape.
For instance, in January 2021, Biogen Inc. announced that it had begun with a virtual research study in partnership with Apple with the objective of investigating the role iPhone and Apple Watch would play in checking the cognitive performance as well as screening for declination in cognitive health including mild cognitive impairment (MCI).
Digital biomarkers market report highlights Abbott Laboratories, AliveCor Inc., Alphabet Inc., Bayer AG, Biogen Inc., Evidation Health, Inc., Eli, Lilly and Company, GSK plc, Novartis AG, and Pfizer Inc. based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2023 | US$ 2.1 Bn |
| Market Forecast (Value) in 2034 | US$ 43.3 Bn |
| Growth Rate (CAGR) | 31.4% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 2.1 Bn in 2023
It is projected to grow at a CAGR of 31.4% from 2024 to 2034
Growing prevalence of chronic diseases and adoption of digital healthcare solutions
Healthcare providers segment accounted for the largest share in 2023
North America was the dominant region in 2023
Abbott Laboratories, AliveCor Inc., Alphabet Inc., Bayer AG, Biogen Inc., Evidation Health, Inc., Eli, Lilly and Company, GSK plc, Novartis AG, and Pfizer Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Digital Biomarkers Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Digital Biomarkers Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product /Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Digital Biomarkers Market Analysis and Forecast, by Component
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Component, 2020-2034
6.3.1. Biosensors
6.3.2. Wearables
6.3.3. Smartphones & Smartwatches
6.3.4. Others (Implantables, etc.)
6.4. Market Attractiveness Analysis, by Component
7. Global Digital Biomarkers Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Application, 2020-2034
7.3.1. Cardiovascular
7.3.2. Sleep and Movement Disorder
7.3.3. Pain Management
7.3.4. Gastrointestinal
7.3.5. Neurodegenerative
7.3.6. Diabetic
7.3.7. Others (Pulmonary, etc.)
7.4. Market Attractiveness Analysis, by Application
8. Global Digital Biomarkers Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2020-2034
8.3.1. Healthcare Companies
8.3.2. Healthcare Providers
8.3.3. Payers
8.3.4. Others (Patients, etc.)
8.4. Market Attractiveness Analysis, by End-user
9. Global Digital Biomarkers Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2020-2034
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Digital Biomarkers Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Component, 2020-2034
10.3.1. Biosensors
10.3.2. Wearables
10.3.3. Smartphones & Smartwatches
10.3.4. Others (Implantables, etc.)
10.4. Market Value Forecast, by Application, 2020-2034
10.4.1. Cardiovascular
10.4.2. Sleep and Movement Disorder
10.4.3. Pain Management
10.4.4. Gastrointestinal
10.4.5. Neurodegenerative
10.4.6. Diabetic
10.4.7. Others (Pulmonary, etc.)
10.5. Market Value Forecast, by End-user, 2020-2034
10.5.1. Healthcare Companies
10.5.2. Healthcare Providers
10.5.3. Payers
10.5.4. Others (Patients, etc.)
10.6. Market Value Forecast, by Country, 2020-2034
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Component
10.7.2. By Application
10.7.3. By End-user
10.7.4. By Country
11. Europe Digital Biomarkers Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Component, 2020-2034
11.3.1. Biosensors
11.3.2. Wearables
11.3.3. Smartphones & Smartwatches
11.3.4. Others (Implantables, etc.)
11.4. Market Value Forecast, by Application, 2020-2034
11.4.1. Cardiovascular
11.4.2. Sleep and Movement Disorder
11.4.3. Pain Management
11.4.4. Gastrointestinal
11.4.5. Neurodegenerative
11.4.6. Diabetic
11.4.7. Others (Pulmonary, etc.)
11.5. Market Value Forecast, by End-user, 2020-2034
11.5.1. Healthcare Companies
11.5.2. Healthcare Providers
11.5.3. Payers
11.5.4. Others (Patients, etc.)
11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Component
11.7.2. By Application
11.7.3. By End-user
11.7.4. By Country/Sub-region
12. Asia Pacific Digital Biomarkers Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Component, 2020-2034
12.3.1. Cardiovascular
12.3.2. Sleep and Movement Disorder
12.3.3. Pain Management
12.3.4. Gastrointestinal
12.3.5. Neurodegenerative
12.3.6. Diabetic
12.3.7. Others (Pulmonary, etc.)
12.4. Market Value Forecast, by End-user, 2020-2034
12.4.1. Healthcare Companies
12.4.2. Healthcare Providers
12.4.3. Payers
12.4.4. Others (Patients, etc.)
12.5. Market Value Forecast, by Country/Sub-region, 2020-2034
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Component
12.6.2. By Application
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Digital Biomarkers Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Component, 2020-2034
13.3.1. Biosensors
13.3.2. Wearables
13.3.3. Smartphones & Smartwatches
13.3.4. Others (Implantables, etc.)
13.4. Market Value Forecast, by Application, 2020-2034
13.4.1. Cardiovascular
13.4.2. Sleep and Movement Disorder
13.4.3. Pain Management
13.4.4. Gastrointestinal
13.4.5. Neurodegenerative
13.4.6. Diabetic
13.4.7. Others (Pulmonary, etc.)
13.5. Market Value Forecast, by End-user, 2020-2034
13.5.1. Healthcare Companies
13.5.2. Healthcare Providers
13.5.3. Payers
13.5.4. Others (Patients, etc.)
13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Component
13.7.2. By Application
13.7.3. By End-user
13.7.4. By Country/Sub-region
14. Middle East & Africa Digital Biomarkers Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Component, 2020-2034
14.3.1. Biosensors
14.3.2. Wearables
14.3.3. Smartphones & Smartwatches
14.3.4. Others (Implantables, etc.)
14.4. Market Value Forecast, by Application, 2020-2034
14.4.1. Cardiovascular
14.4.2. Sleep and Movement Disorder
14.4.3. Pain Management
14.4.4. Gastrointestinal
14.4.5. Neurodegenerative
14.4.6. Diabetic
14.4.7. Others (Pulmonary, etc.)
14.5. Market Value Forecast, by End-user, 2020-2034
14.5.1. Healthcare Companies
14.5.2. Healthcare Providers
14.5.3. Payers
14.5.4. Others (Patients, etc.)
14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Component
14.7.2. By Application
14.7.3. By End-user
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2023)
15.3. Company Profiles
15.3.1. Abbott Laboratories
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. AliveCor Inc.
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Alphabet Inc.
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Bayer AG
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Biogen Inc.
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Evidation Health, Inc.
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Eli, Lilly and Company
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. GSK plc
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Novartis AG
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Pfizer Inc.
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
List of Tables
Table 01: Global Digital Biomarkers Market Size (US$ Bn) Forecast, by Component, 2020-2034
Table 02: Global Digital Biomarkers Market Size (US$ Bn) Forecast, by Application, 2020-2034
Table 03: Global Digital Biomarkers Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 04: Global Digital Biomarkers Market Size (US$ Bn) Forecast, by Region, 2020-2034
Table 05: North America Digital Biomarkers Market Size (US$ Bn) Forecast, by Country, 2020-2034
Table 06: North America Digital Biomarkers Market Size (US$ Bn) Forecast, by Component, 2020-2034
Table 07: North America Digital Biomarkers Market Size (US$ Bn) Forecast, by Application, 2020-2034
Table 08: North America Digital Biomarkers Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 09: Europe Digital Biomarkers Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 10: Europe Digital Biomarkers Market Size (US$ Bn) Forecast, by Component, 2020-2034
Table 11: Europe Digital Biomarkers Market Size (US$ Bn) Forecast, by Application, 2020-2034
Table 12: Europe Digital Biomarkers Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 13: Asia Pacific Digital Biomarkers Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 14: Asia Pacific Digital Biomarkers Market Size (US$ Bn) Forecast, by Component, 2020-2034
Table 15: Asia Pacific Digital Biomarkers Market Size (US$ Bn) Forecast, by Application, 2020-2034
Table 16: Asia Pacific Digital Biomarkers Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 17: Latin America Digital Biomarkers Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 18: Latin America Digital Biomarkers Market Size (US$ Bn) Forecast, by Component, 2020-2034
Table 19: Latin America Digital Biomarkers Market Size (US$ Bn) Forecast, by Application, 2020-2034
Table 20: Latin America Digital Biomarkers Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 21: Middle East & Africa Digital Biomarkers Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 22: Middle East & Africa Digital Biomarkers Market Size (US$ Bn) Forecast, by Component, 2020-2034
Table 23: Middle East & Africa Digital Biomarkers Market Size (US$ Bn) Forecast, by Application, 2020-2034
Table 24: Middle East & Africa Digital Biomarkers Market Size (US$ Bn) Forecast, by End-user, 2020-2034
List of Figures
Figure 01: Global Digital Biomarkers Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2034
Figure 02: Global Digital Biomarkers Market Revenue (US$ Bn), by Component, 2023
Figure 03: Global Digital Biomarkers Market Value Share, by Component, 2023
Figure 04: Global Digital Biomarkers Market Revenue (US$ Bn), by Application, 2023
Figure 05: Global Digital Biomarkers Market Value Share, by Application, 2023
Figure 06: Global Digital Biomarkers Market Revenue (US$ Bn), by End-user, 2023
Figure 07: Global Digital Biomarkers Market Value Share, by End-user, 2023
Figure 08: Global Digital Biomarkers Market Value Share, by Region, 2023
Figure 09: Global Digital Biomarkers Market Value (US$ Bn) Forecast, 2020-2034
Figure 10: Global Digital Biomarkers Market Value Share Analysis, by Component, 2023 and 2034
Figure 11: Global Digital Biomarkers Market Attractiveness Analysis, by Region, 2024-2034
Figure 12: Global Digital Biomarkers Market Value Share Analysis, by Application, 2023 and 2034
Figure 13: Global Digital Biomarkers Market Attractiveness Analysis, by Application, 2024-2034
Figure 14: Digital Biomarkers Market Value Share Analysis, by End-user, 2023 and 2034
Figure 15: Global Digital Biomarkers Market Attractiveness Analysis, by End-user, 2024-2034
Figure 16: Global Digital Biomarkers Market Value Share Analysis, by Region, 2023 and 2034
Figure 17: Global Digital Biomarkers Market Attractiveness Analysis, by Region, 2024-2034
Figure 18: North America Digital Biomarkers Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 19: North America Digital Biomarkers Market Attractiveness Analysis, by Country, 2024-2034
Figure 20: North America Digital Biomarkers Market Value Share Analysis, by Country, 2023 and 2034
Figure 21: North America Digital Biomarkers Market Value Share Analysis, by Component, 2023 and 2034
Figure 22: North America Digital Biomarkers Market Value Share Analysis, by Application, 2023 and 2034
Figure 23: North America Digital Biomarkers Market Value Share Analysis, by End-user, 2023 and 2034
Figure 24: North America Digital Biomarkers Market Attractiveness Analysis, by Region, 2024-2034
Figure 25: North America Digital Biomarkers Market Attractiveness Analysis, by Application, 2024-2034
Figure 26: North America Digital Biomarkers Market Attractiveness Analysis, by End-user, 2024-2034
Figure 27: Europe Digital Biomarkers Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 28: Europe Digital Biomarkers Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 29: Europe Digital Biomarkers Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 30: Europe Digital Biomarkers Market Value Share Analysis, by Component, 2023 and 2034
Figure 31: Europe Digital Biomarkers Market Value Share Analysis, by Application, 2023 and 2034
Figure 32: Europe Digital Biomarkers Market Value Share Analysis, by End-user, 2023 and 2034
Figure 33: Europe Digital Biomarkers Market Attractiveness Analysis, by Region, 2024-2034
Figure 34: Europe Digital Biomarkers Market Attractiveness Analysis, by Application, 2024-2034
Figure 35: Europe Digital Biomarkers Market Attractiveness Analysis, by End-user, 2024-2034
Figure 36: Asia Pacific Digital Biomarkers Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 37: Asia Pacific Digital Biomarkers Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 38: Asia Pacific Digital Biomarkers Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 39: Asia Pacific Digital Biomarkers Market Value Share Analysis, by Component, 2023 and 2034
Figure 40: Asia Pacific Digital Biomarkers Market Value Share Analysis, by Application, 2023 and 2034
Figure 41: Asia Pacific Digital Biomarkers Market Value Share Analysis, by End-user, 2023 and 2034
Figure 42: Asia Pacific Digital Biomarkers Market Attractiveness Analysis, by Region, 2024-2034
Figure 43: Asia Pacific Digital Biomarkers Market Attractiveness Analysis, by Application, 2024-2034
Figure 44: Asia Pacific Digital Biomarkers Market Attractiveness Analysis, by End-user, 2024-2034
Figure 45: Latin America Digital Biomarkers Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 46: Latin America Digital Biomarkers Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 47: Latin America Digital Biomarkers Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 48: Latin America Digital Biomarkers Market Value Share Analysis, by Component, 2023 and 2034
Figure 49: Latin America Digital Biomarkers Market Value Share Analysis, by Application, 2023 and 2034
Figure 50: Latin America Digital Biomarkers Market Value Share Analysis, by End-user, 2023 and 2034
Figure 51: Latin America Digital Biomarkers Market Attractiveness Analysis, by Region, 2024-2034
Figure 52: Latin America Digital Biomarkers Market Attractiveness Analysis, by Application, 2024-2034
Figure 53: Latin America Digital Biomarkers Market Attractiveness Analysis, by End-user, 2024-2034
Figure 54: Middle East & Africa Digital Biomarkers Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 55: Middle East & Africa Digital Biomarkers Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 56: Middle East & Africa Digital Biomarkers Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 57: Middle East & Africa Digital Biomarkers Market Value Share Analysis, by Component, 2023 and 2034
Figure 58: Middle East & Africa Digital Biomarkers Market Value Share Analysis, by Application, 2023 and 2034
Figure 59: Middle East & Africa Digital Biomarkers Market Value Share Analysis, by End-user, 2023 and 2034
Figure 60: Middle East & Africa Digital Biomarkers Market Attractiveness Analysis, by Region, 2024-2034
Figure 61: Middle East & Africa Digital Biomarkers Market Attractiveness Analysis, by Application, 2024-2034
Figure 62: Middle East & Africa Digital Biomarkers Market Attractiveness Analysis, by End-user, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Digital Biomarkers Market
